intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs.
1997;54:634.
Murphy MB et al. Fenoldopam—a selective peripheral dopamine-receptor agonist for the treatment of severe
hypertension. N EnglJ Med. 2001;345:1548.
Nichols AJ et al. The pharmacology of fenoldopam. Am J Hypertens. 1990;3:116S.
White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and
sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989;149:870.
Oparil S et al. A new parenteral antihypertensive: consensus roundtable on the management of perioperative
hypertension and hypertensive crises. Am J Hypertens. 1999;12:653.
Bovet T et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury
after cardiac surgery: a randomized clinical trial. JAMA. 2014;312:2244–2253.
Yakazu Y et al. Hemodynamic and sympathetic effects of fenoldopam and sodium nitroprusside. Acta
Anaesthesiol Scand. 2001;45:1176.
Everitt DE et al. Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension. J Clin
Pharmacol. 1997;37:312.
Piltz JR et al. Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with
normal intraocular pressure. J Ocul Pharmacol Ther. 1998;14:203.
Cressman MD et al. Intravenous labetalol in the management of severe hypertension and hypertensive
emergencies. Am Heart J. 1984;107:980.
Wilson DJ et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am
J Med. 1983;75(4A):95.
Smith WB et al. Antihypertensive effectiveness of intravenous labetalol in accelerated hypertension.
Hypertension. 1983;5:579.
Dal Palu C et al. Intravenous labetalol in severe hypertension. Br J Clin Pharmacol. 1982;13(1, Suppl):97S.
Lebel M et al. Labetalol infusion in hypertensive emergencies. Clin Pharmacol Ther. 1985;37:615.
Vidt DG. Intravenous labetalol in the emergency treatment of hypertension. J Clin Hypertens. 1985;1:179.
Patel RV et al. Labetalol: response and safety in critically ill hemorrhagic stroke patients. Ann Pharmacother.
1993;27:180.
Kanto JH. Current status of labetalol, the first alpha-and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol.
1985;23:617.
George RB et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of
hypertensive patients with asthma and propranololsensitivity. Chest. 1985;88:815.
Walstad RA et al. Labetalol in the treatment of hypertension in patients with normal and impaired renal function.
Acta Med Scand Suppl. 1982;665:135.
Wood AJ et al. Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol. 1982;13(1,
Suppl):81S.
MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology pharmacokinetics, clinical uses and
adverse effects. Pharmacotherapy. 1983;3:193.
Eisalo A, Virta P. Treatment of hypertension in the elderly with labetalol. Acta Med Scand Suppl. 1982;665:129.
Abrams JH et al. Successful treatment of a monoamine oxidase inhibitor-tyramine hypertensive emergency with
intravenous labetalol. N EnglJ Med. 1985;313:52.
Navaratnarajah M, White DC. Labetalol and phaeochromocytoma. Br J Anaesth. 1984;56:1179.
Pearson RM, Havard CW. Intravenous labetalol in hypertensive patients treated with beta-adrenoceptor
blocking drugs. Br J Clin Pharmacol. 1976;3(4, Suppl 3):795.
Cumming AM et al. Intravenous labetalol in the treatment of severe hypertension. Br J Clin Pharmacol.
1982;13(1, Suppl):93S.
Flaherty JT et al. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute
hypertension developing after coronary artery bypass surgery. Circulation. 1982;65:1072.
Chun G, Frishman WH. Rapid-acting parenteral antihypertensive agents. J Clin Pharmacol. 1990;30:195.
Francis GS. Vasodilators in the intensive care unit. Am Heart J. 1991;121:1875.
Rutledge J et al. Effect of intravenous enalaprilat in moderate and severe hypertension. Am J Cardiol.
1988;62:1062.
Evans RR et al. The effect of intravenous enalaprilat (MK-422) administration in patients with mild to moderate
essential hypertension. J Clin Pharmacol. 1987;27:415.
Hirschl MM et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
crises. Arch Intern Med. 1995;155:2217.
White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.
Pharmacotherapy. 1998;18:588.
Misra M et al. Evaluation of the efficacy, safety, and tolerability of intravenous enalaprilat in the treatment of
grade III essential hypertension in Indian patients. Indian Heart J. 2004;56:67.
DiPette DJ et al. Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin
Pharmacol Ther. 1985;38:199.
Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst
Pharm. 2004;61:1661.
Cheung DG et al. Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine.
Am Heart J. 1990;119:438.
[No authors listed]. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension.
IV Nicardipine Study Group. Chest. 1991;99:393.
Halpern NA et al. Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit
Care Med. 1990;18:950.
Halpern NA et al. Postoperative hypertension: a prospective placebo controlled, randomized, double-blind trial
with intravenous nicardipine hydrochloride. Angiology. 1990;41:992.
Kaplan JA. Clinical considerations for the use of intravenous nicardipine in the treatment of postoperative
hypertension. Am Heart J. 1990;119:443.
Wallin JD et al. Intravenous nicardipine for treatment of severe hypertension. A double-blind, placebo-controlled
multicenter trial. Arch Intern Med. 1989;149:2662.
NeutelJM et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of
severe hypertension. Am J Hypertens. 1994;7:623.
Qureshi AI et al. Treatment of acute hypertension in patients with intracerebral hemorrhage using American
Heart Association guidelines. Crit Care Med. 2006;34:1975.
Curran MP et al. Intravenous nicardipine: its use in the short-term treatment of hypertension and various other
indications. Drugs. 2006;66:1755.
Kwak YL et al. Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood
pressure after coronary artery bypass graft surgery. J Int Med Res. 2004;32:342.
Dorman T et al. Nicardipine versus nitroprusside for breakthrough hypertension following carotid
endarterectomy. J Clin Anesth. 2001;13:16.
Salerno DM et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter.
Am J Cardiol. 1989;63:1046.
Ellenbogen KA et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart
rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891.
Dougherty AH et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem.
IV Diltiazem Study Group. Am J Cardiol. 1992;70:587.
Koh H et al. Clinical study of total intravenous anesthesia with droperidol, fentanyl, and ketamine: control of
intraoperative hypertension with diltiazem [article in Japanese]. Masui. 1991;40:1376.
Boylan JF et al. A comparison of diltiazem, esmolol, nifedipine, and nitroprusside therapy of post-CABG
hypertension. Can J Anaesth. 1990;37:S156.
Jaffe AS. Use of intravenous diltiazem in patients with acute coronary artery disease. Am J Cardiol.
1992;69:25B.
Fang ZY et al. Intravenous diltiazem versus nitroglycerin for silent and symptomatic myocardial ischemia in
unstable angina pectoris. Am J Cardiol. 1991;68:42C.
Onoyama K et al. Effect of drug infusion or a bolus injection of intravenous diltiazem on hypertensive crisis.
No comments:
Post a Comment
اكتب تعليق حول الموضوع